The maker of a popular flea and tick treatment has stated that the drug is safe amid allegations that it could cause mortality in dogs.

WCNC recently reported about the stories of people who have lost their pet dogs after giving them the chewable anti-parasitic tablet. One of those people is Donald Junker, who narrated that his wife gave their dog the tablets and found it dead the next morning. "We haven't changed his diet, we haven't changed a thing, so yes, we believe it's Bravecto," he said.

Like Us on Facebook

According to Jim Strickland of WSB-TV, the drug is believed to be responsible for up to 355 deaths. Meanwhile, European regulators have voted to include lethargy on the label as an additional side effect of the drug after receiving 800 reports of death from around the world.

Drug maker Merck Animal health told NBC Charlotte that "our post-approval studies and post-approval surveillance have provided additional compelling evidence that supports the safety profile of Bravecto."

The pharmaceutical giant answered to Strickland via email saying that there was less than .01 percent of adverse events reported since 34 million doses of the drug was released in 2014. Further, the company said that it would have put label warning on the drug if it was necessary.

Similarly, a veterinarian from Lesslie Animal Hospital named Dr. Setzer believes that there is still no basis for the allegations and that he still uses the medicine. "In almost all the cases, no necropsy or autopsy were done because the owners refused to have those done. Without necropsy or autopsy, you can't find out what the cause of death was," he explained.

Bravecto is a chewable tablet that can treat flea and tick infestation and repel the parasite for 12 weeks. The drug can kick-off three types of ticks including the American dog tick, brown dog tick, and deer tick for 12 weeks. Whereas the lone star tick cannot infest the protected animal for eight weeks.

This anti-parasitic medicine prescribed by licensed veterinarians received approval from the U.S. Food and Drug Administration's Veterinary Medicine in 2014.